173 related articles for article (PubMed ID: 38191764)
1. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.
Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG
J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764
[TBL] [Abstract][Full Text] [Related]
2. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
3. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
5. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
7. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
8. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
9. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
Ben-Naim L; Khalaila I; Papo N
Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
[TBL] [Abstract][Full Text] [Related]
10. Gene Editing for the Treatment of Hypercholesterolemia.
Hoekstra M; Van Eck M
Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
[TBL] [Abstract][Full Text] [Related]
11. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
12. Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
Leung AKK; Xue YC; de Guzman A; Grzelkovski G; Kong HJ; Genga KR; Russell JA; Boyd JH; Francis GA; Walley KR
Atherosclerosis; 2022 Dec; 362():29-37. PubMed ID: 36207148
[TBL] [Abstract][Full Text] [Related]
13. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
Ding Q; Strong A; Patel KM; Ng SL; Gosis BS; Regan SN; Cowan CA; Rader DJ; Musunuru K
Circ Res; 2014 Aug; 115(5):488-92. PubMed ID: 24916110
[TBL] [Abstract][Full Text] [Related]
14. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing.
Mun D; Kang JY; Kim H; Yun N; Joung B
J Control Release; 2024 Jun; 370():798-810. PubMed ID: 38754633
[TBL] [Abstract][Full Text] [Related]
15. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
16. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Chadwick AC; Musunuru K
Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
19. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
Wang L; Breton C; Warzecha CC; Bell P; Yan H; He Z; White J; Zhu Y; Li M; Buza EL; Jantz D; Wilson JM
Mol Ther; 2021 Jun; 29(6):2019-2029. PubMed ID: 33609733
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
